PROC and acute respiratory distress syndrome: In a secondary analysis of the PROWESS-SHOCK trial, investigating recombinant human activated protein C (drotrecogin alfa activated-DrotAA) vs. a placebo in septic shock, a significant treatment interaction effect was observed with ARDS molecular phenotype assignment; DrotAA was associated with higher mortality in the hypoinflammatory and lower mortality in the hyperinflammatory subphenotype, compared with a placebo [49].